Source link : https://www.newshealth.biz/health-news/nivolumab-nsclc-approval-expanded-to-perioperative-setting/
The US Food and Drug Administration (FDA) has expanded the approval of nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of certain patients with resectable non–small cell lung cancer (NSCLC). Specifically, the immune checkpoint inhibitor — a programmed death receptor-1 (PD-1) blocking monoclonal antibody — has been approved for use in combination with platinum-doublet chemotherapy […]
Author : News Health
Publish date : 2024-10-03 19:18:15
Copyright for syndicated content belongs to the linked Source.